Clinical trials sponsored by UNICANCER

Phase breakdown

Conditions studied

Recruiting trials led by UNICANCER

• A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
  NCT05639413 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 45 locations
• ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
  NCT04916613 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 95 locations
• Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
  NCT05800275 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Chronic Toxicities Related to Treatment in Patients With Localized Cancer
  NCT01993498 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 2 locations
• Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
  NCT07192068 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
  NCT06450314 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme
  NCT06475352 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
  NCT06333314 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 44 locations
• Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
  NCT07230613 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
  NCT07259226 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
  NCT07106632 · Phase: Phase 3 · Ages: 35 Years to 45 Years · Sex: Female · 105 locations
• Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
  NCT06078384 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 44 locations
• Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
  NCT06606730 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
  NCT06245356 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer
  NCT07661927 · Phase: Phase 2 · Ages: 60 Years and older · Sex: Female · 41 locations
• Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
  NCT06496581 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Male · 25 locations
• Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
  NCT06625970 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Male · 6 locations
• TARGETed Therapy Drug MONITOring in DIGestive Oncology
  NCT05443087 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 29 locations
• Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
  NCT06276465 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 4 locations

Common questions

How many trials is UNICANCER recruiting for?

UNICANCER is the lead sponsor of 19 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.